Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 212-634-7 | CAS number: 834-12-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- December 1999
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP study in compliance with guidelines
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 999
- Report date:
- 1999
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Deviations:
- no
- GLP compliance:
- no
- Limit test:
- no
Test material
- Reference substance name:
- Ametryn
- EC Number:
- 212-634-7
- EC Name:
- Ametryn
- Cas Number:
- 834-12-8
- Molecular formula:
- C9H17N5S
- IUPAC Name:
- N2-ethyl-6-(methylsulfanyl)-N4-(propan-2-yl)-1,3,5-triazine-2,4-diamine
- Details on test material:
- Name: Ametryn technical
CAS No. : 834-12-8
Manufactured and : Oxon Italia SpA
Lot No. : S349
Date of manufacture : October, 1996
Date of expiry : October, 1998
Declared purity : 96% (960 g/kg)
Physical appearance : Solid, white powder
Solubility : Soluble in water at 185 mg/L and also soluble in acetone at 500 g/L
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: hsdcpb: WU rats conventionally bred
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Age at the start of the experiment : 5 - 6 weeks
Mean body weights (g)
± SD at the start of treatment :
Males Females
G1: 92 ± 8.6g 87 ±8.5g
G2: 93 ± 9.7g 88 ± 9.5g
G3 93 ± 9.7g 87 ± 9.9g
G4: 94 ± 9.3g 87 ± 8.8g
G5: 92 ±11.7g 87 ± 6.5g
Identification : Rat accession number, cage card and corresponding picric acid body markings.
Acclimatization : Five days under experimental conditions after veterinary examination.
Animal selection : Before initiation of the treatment, the rats were stratified according to their body weights and assigned to 5 groups of twelve rats each (6 males and 6 females).
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- The test compound was mixed in the laboratory animal feed at concentrations of 750 (G2), 1500 (G3), 3000 (G4) and 6000 (G5) ppm and fed to 4 groups of rats. A concurrent control group (G1) received laboratory animal feed without the test compound admixture.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The test compound (Ametryn) extracted from the experimental rats/mice feed with acetone was estimated by means of GLC with Nitrogen Phosphorus Detector (NPD). The achieved concentrations were within the permissible 10% range of nominal concentrations.
The identity of the test compound was confirmed prior to the start of the study. The stability of the test compound in experimental feed was analysed prior to the start of the study. Dietary concentrations of the test compound (Active Ingredient) were determined twice during the study period. Homogeneity in the experimental feed was analysed at the first batch of feed preparation. Three samples from top, middle and bottom layers of the fortified feed from all the tested doses were used for determining homogeneity. - Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- All test groups received the experimental feed specifically prepared for each group ad libitum. The treatment was given 7 days a week for 4 weeks.
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0 ppm (G1), 750 ppm (G2), 1500 ppm (G3), 3000 ppm (G4), 6000 ppm (G5)
Basis:
nominal in diet
- No. of animals per sex per dose:
- 12 rats (6 males, 6 female)
- Control animals:
- other: yes, a concurrent control group (G1) received laboratory animal feed without the test compound admixture.
- Details on study design:
- G1: Vehicle control
G2: Low dose
G3: Mid dose
G4: High Intermediate
G5: High dose - Positive control:
- No positive control
Examinations
- Observations and examinations performed and frequency:
- Veterinary examination was done before grouping and at the end of each week of the experimental schedule as per the standard operating procedure and the findings were recorded.
Ophthalmological examination of all animals was done at the start of the experiment and at the end of the treatment prior to sacrifice with ophthalmoscope. Mydriasis was produced before examination using 1% Tropicamide solution (Akhil Farma Pvt. Ltd., Muttangi 502300, INDIA).
Clinical signs and pre-terminal deaths: Rats were observed for clinical signs and pre-terminal deaths once daily. - Sacrifice and pathology:
- Gross necropsy: The animals at term were fasted overnight (water provided) and exanguinated under ether anaesthesia and were subjected to detailed necropsy by a pathologist.
Organ weights: The following organs were collected and weighed: adrenals, gonads, liver, spleen, kidneys, epididymides, thymus, brain and heart The organ weight ratios as percentages of body weights were determined and recorded. - Other examinations:
- Individual body weights were recorded at the beginning and at the end of each week of the study.
The weekly feed consumption was calculated by adding the feed consumed in I (4 days) and II (3 days) and the total divided by the number of rats per cage to determine the feed intake/rat/week. The weekly feed consumption (g/rat) was divided by the number of days (7) and expressed as (g/rat/day). This was repeated during each week of the experimental period. - Statistics:
- Using specific computer programmes, body weights, net body weight gains, feed consumption, organ weight data and organ weight ratio values were compared by Bartletts test for homogeneity of intra group variances. When the variances proved to be heterogeneous, the data were transformed using appropriate transformation. The data with homogeneous intra group variances were subjected to one-way analysis of variance (ANOVA - Snedecor and Cochran, 1980).
Following ANOVA, when F value was significant, Dunnetts pairwise comparison (Scheffe, 1953) of means of treated groups with the control mean was done individually. Following a significant difference of a test group with the control group, the dose response correlation was estimated by including the control and all the treated groups employing t test.
All analyses and comparisons were evaluated at the 5% level. Throughout this report statistically significant differences, indicated by the aforementioned tests were designated by the superscripts as stated below:
+/- : Significantly higher (+)/lower (-) than the control group
d : Significant dose correlation.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- effects observed, treatment-related
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- Veterinary and ophthalmological examinations, clinical signs and pre4erminal deaths:
Emaciated condition was observed in three males and all the females and an isolated incidence of perineum wet was observed in one female and 3/6 males and 6/6 females died pre-terminally (one male on day 7 and one female on day 9 were sacrificed moribund due to emaciation between the 5th and 10th day of the treatment period) in which 2 males and 3 females were autolysed at the 6000 ppm dose.
The pre-terminal deaths at the high dose could be due to the unpalatable nature of the test compound which resulted in weakness and emaciation brought about by inanition.
Body weights and cumulative net weight gains:
Individual body weights were recorded at the beginning and at the end of each week of the experiment.
At the 1500 ppm dose, the body weights were significantly lower at weeks 1 and 3 and cumulative net weight gains were lower throughout the treatment period in males and at weeks 1 and 2 in females.
At the 3000 ppm dose, the body weights and cumulative net weights gains were significantly lower throughout the treatment period in both the sexes.
At the 6000 ppm dose, the body weights and cumulative net body weight gains were significantly lower throughout the treatment period in males and at week 1 of the females.
The decrease observed in the mean weekly body weights and cumulative net body weight gains in both sexes were dose-related.
The decrease observed could be partly due to less feed consumption and the general/mild toxicity of the test compound.
Feed intake:
- Males: At the 3000 and 6000 ppm doses, the feed consumption was significantly lower throughout the treatment period. The decrease observed was dose- related for 2nd, 3rd and 4th week of the experimental period.
- Females: At the 3000 and 6000 ppm doses, the feed consumption was significantly lower for the first 2 weeks of the treatment period. -
The decrease observed could be due to the unpalatability of the test compound at the respective dose levels.
Efficiency of feed utilization: The feed conversion efficiency was not altered by the treatment.
Terminal fasting body weights, organ weights and organ weight ratios:
The terminal fasting body weights were significantly lower at the 3000 ppm and 6000 ppm doses in males and at the 3000 ppm dose in females. The decrease in the fasting body weights in males was dose-related.
In males, the absolute weight of adrenals, kidneys, liver, heart, brain and spleen at the 3000 ppm and 6000 ppm doses, testes and epididymes at the 6000 ppm dose, thymus at all the doses were significantly lower. The relative weight of kidneys, liver, heart and brain at the 3000 and 6000 ppm doses, adrenals at the 6000 ppm dose, testes at the 3000 ppm dose and liver at the 1500 ppm dose were significantly higher The relative weight of epididymides at the 6000 ppm dose, thymus at the 750 and 6000 ppm doses were significantly lower. The changes observed were dose-related excepting for changes in the relative weight of thymus and testes.
In females, the absolute weight of adrenals, ovaries, thymus and spleen at 1500 and 3000 ppm doses, heart at the 750 and 3000 ppm doses, brain at 3000 ppm dose were significantly lower. The absolute weight of liver at the 1500 and 3000 ppm doses were significantly higher. The relative weights of adrenals, ovaries and spleen at the 1500 ppm dose and adrenals at the 3000 ppm dose were significantly lower. The relative weight of liver was significantly higher at the 1500 and 3000 ppm doses.
The significant reduction in the fasting body weights were in turn reflected in the changes in the organ weights.
Necropsy:
- External pathology: Emaciated condition was observed in three males and all the females at the 6000 ppm dose.
- Visceral organ pathology: No gross pathological changes were observed in any of the doses tested. Two females were partially cannibalised at the 6000 ppm dose.
Effect levels
- Dose descriptor:
- NOEL
- Effect level:
- 750 ppm
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
